SEMA3A and neoplasm: These unhelpful effects of sunitinib were overcome with combined SEMA3A treatment, with the combination demonstrating not only a reduced tumour burden and reduced angiogenesis but also reduced cancer invasion into surrounding tissue, including lymph node and liver metastases [55].